The Manila Times

MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell (MPC)-based Tissue-Engineered Therapy Showing Clinically Meaningf…

Zurich, Switzerland, December 03, 2025 - MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive ...

MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell (MPC)-based Tissue-Engineered Therapy Showing Clinically Meaningful and ...

MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269)evaluating its novel proprietary muscle ...
PharmiWeb

Surgical Robots Market Size, Share, and Growth Forecast 2025-2030

The global surgical robotics market is forecast to grow at a compound annual growth rate (CAGR) of 15% between 2025 and 2030.
Pharmabiz

US FDA approves Cleveland Diagnostics’ novel blood-based prostate cancer test, IsoPSA

US FDA approves Cleveland Diagnostics’ novel blood-based prostate cancer test, IsoPSA: Cleveland Tuesday, December 2, 2025, 17:00 Hrs [IST] Cleveland Diagnostics, Inc., a pionee ...

Wharfedale Hospital's surgical hub gets national recognition

WHARFEDALE Hospital’s surgical hub has been successfully accredited for delivering high standards in clinical and operational practice as part ...